Teleflex Incorporated (TFX) PT Raised to $295.00 at Jefferies Group LLC
Teleflex Incorporated (NYSE:TFX) had its price objective boosted by Jefferies Group LLC from $270.00 to $295.00 in a research report issued on Friday. The firm presently has a “buy” rating on the medical technology company’s stock. Jefferies Group LLC’s price objective suggests a potential upside of 15.05% from the company’s current price. Jefferies Group also issued estimates for Teleflex’s Q2 2018 earnings at $2.31 EPS and Q4 2018 earnings at $2.87 EPS.
Other analysts have also issued research reports about the stock. Zacks Investment Research raised shares of Teleflex from a “hold” rating to a “buy” rating and set a $261.00 price target for the company in a report on Tuesday, September 12th. BidaskClub lowered shares of Teleflex from a “hold” rating to a “sell” rating in a report on Tuesday, August 8th. Barclays PLC reissued an “overweight” rating and issued a $253.00 price target (up previously from $230.00) on shares of Teleflex in a report on Tuesday, September 12th. Needham & Company LLC reissued a “buy” rating on shares of Teleflex in a report on Friday, August 4th. Finally, Deutsche Bank AG reissued a “buy” rating and issued a $251.00 price target (up previously from $238.00) on shares of Teleflex in a report on Monday, September 18th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $271.88.
Teleflex (NYSE TFX) opened at $256.41 on Friday. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.76 and a current ratio of 4.72. The company has a market cap of $11,551.01, a PE ratio of 31.69, a P/E/G ratio of 2.46 and a beta of 1.05.
Teleflex (NYSE:TFX) last posted its earnings results on Thursday, November 2nd. The medical technology company reported $2.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.01 by $0.11. Teleflex had a net margin of 12.41% and a return on equity of 16.27%. The company had revenue of $534.70 million during the quarter, compared to analysts’ expectations of $522.94 million. During the same quarter in the previous year, the company posted $1.80 earnings per share. Teleflex’s quarterly revenue was up 17.3% compared to the same quarter last year. equities analysts expect that Teleflex will post 8.31 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/11/05/teleflex-incorporated-tfx-pt-raised-to-295-00-at-jefferies-group-llc.html.
In other Teleflex news, Director Stephen K. M.D. Klasko sold 200 shares of Teleflex stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $237.18, for a total transaction of $47,436.00. Following the completion of the sale, the director now owns 8,080 shares of the company’s stock, valued at approximately $1,916,414.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 600 shares of company stock valued at $138,162 in the last ninety days. Company insiders own 2.39% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Toronto Dominion Bank grew its holdings in Teleflex by 14.5% during the 2nd quarter. Toronto Dominion Bank now owns 552 shares of the medical technology company’s stock worth $115,000 after acquiring an additional 70 shares during the period. Advisory Services Network LLC grew its holdings in Teleflex by 933.8% during the 2nd quarter. Advisory Services Network LLC now owns 827 shares of the medical technology company’s stock worth $172,000 after acquiring an additional 747 shares during the period. Cornerstone Capital Management Holdings LLC. acquired a new stake in Teleflex during the 2nd quarter worth $175,000. OLD Mutual Customised Solutions Proprietary Ltd. grew its holdings in Teleflex by 200.0% during the 1st quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 900 shares of the medical technology company’s stock worth $174,000 after acquiring an additional 600 shares during the period. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in Teleflex during the 2nd quarter worth $200,000. 89.78% of the stock is owned by hedge funds and other institutional investors.
Teleflex Company Profile
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.